{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:49:14Z","timestamp":1771512554215,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"DOI":"10.1093\/molehr\/gah199","type":"journal-article","created":{"date-parts":[[2005,7,28]],"date-time":"2005-07-28T20:38:25Z","timestamp":1122583105000},"page":"561-566","source":"Crossref","is-referenced-by-count":20,"title":["Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-\u03b3 ligand, pioglitazone"],"prefix":"10.1093","volume":"11","author":[{"given":"C.J.","family":"Loy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Evelyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.H.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.L.","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,6,28]]},"reference":[{"key":"key\n\t\t\t\t20171013084702_BRUEMMER-LAW-2003","doi-asserted-by":"crossref","unstructured":"Bruemmer D and Law RE (2003) Thiazolidinedione regulation of smooth muscle cell proliferation. Am J Med115,87S\u201392S.","DOI":"10.1016\/j.amjmed.2003.09.014"},{"key":"key\n\t\t\t\t20171013084702_BUDDE-ET-AL-2003","doi-asserted-by":"crossref","unstructured":"Budde K , Neumayer HH, Fritsche L, Sulowicz W, Stompor T and Eckland D (2003) The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol55,368\u2013374.","DOI":"10.1046\/j.1365-2125.2003.01785.x"},{"key":"key\n\t\t\t\t20171013084702_CARNEY-ET-AL-2002","doi-asserted-by":"crossref","unstructured":"Carney SA , Tahara H, Swartz CD, Risinger JI, He H, Moore AB, Haseman JK, Barrett JC and Dixon D (2002) Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics. Lab Invest82,719\u2013728.","DOI":"10.1097\/01.LAB.0000017499.51216.3E"},{"key":"key\n\t\t\t\t20171013084702_CHAN-ET-AL-1993","unstructured":"Chan YG , Ho HK and Chen CY (1993) Abdominal hysterectomy: indications and complications. Singapore Med J34,337\u2013340."},{"key":"key\n\t\t\t\t20171013084702_CHEGINI-ET-AL-2002","doi-asserted-by":"crossref","unstructured":"Chegini N , Ma C, Tang XM and Williams RS (2002) Effects of GnRH analogues, \u2018add-back\u2019 steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod8,1071\u20131078.","DOI":"10.1093\/molehr\/8.12.1071"},{"key":"key\n\t\t\t\t20171013084702_DANG-ET-AL-2003","doi-asserted-by":"crossref","unstructured":"Dang ZC , Audinot V, Papapoulos SE, Boutin JA and Lowik CW (2003) Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J Biol Chem278,962\u2013967.","DOI":"10.1074\/jbc.M209483200"},{"key":"key\n\t\t\t\t20171013084702_DIAMANT-HEINE-2003","doi-asserted-by":"crossref","unstructured":"Diamant M and Heine RJ (2003) Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs63,1373\u20131405.","DOI":"10.2165\/00003495-200363130-00004"},{"key":"key\n\t\t\t\t20171013084702_DIXON-ET-AL-2002","doi-asserted-by":"crossref","unstructured":"Dixon D , Flake GP, Moore AB, He H, Haseman JK, Risinger JI, Lancaster JM, Berchuck A, Barrett JC and Robboy SJ (2002) Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch441,53\u201362.","DOI":"10.1007\/s00428-001-0568-7"},{"key":"key\n\t\t\t\t20171013084702_FALCONE-BEDAIWY-2002","doi-asserted-by":"crossref","unstructured":"Falcone T and Bedaiwy MA (2002) Minimally invasive management of uterine fibroids. Curr Opin Obstet Gynecol14,401\u2013407.","DOI":"10.1097\/00001703-200208000-00007"},{"key":"key\n\t\t\t\t20171013084702_FARQUHAR-STEINER-2002","unstructured":"Farquhar CM and Steiner CA (2002) Hysterectomy rates in the United States 1990\u20131997. Obstet Gynecol99,229\u2013234."},{"key":"key\n\t\t\t\t20171013084702_FUKUHARA-ET-AL-2002","doi-asserted-by":"crossref","unstructured":"Fukuhara K , Kariya M, Kita M, Shime H, Kanamori T, Kosaka C, Orii A, Fujita J and Fujii S (2002) Secreted frizzled related protein 1 is overexpressed in uterine leiomyomas, associated with a high estrogenic environment and unrelated to proliferative activity. J Clin Endocrinol Metab87,1729\u20131736.","DOI":"10.1210\/jcem.87.4.8375"},{"key":"key\n\t\t\t\t20171013084702_GAO-ET-AL-2001","doi-asserted-by":"crossref","unstructured":"Gao Z , Matsuo H, Wang Y, Nakago S and Maruo T (2001) Up-regulation by IGF-I of proliferating cell nuclear antigen and BCL-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab86,5593\u20135599.","DOI":"10.1210\/jcem.86.11.8008"},{"key":"key\n\t\t\t\t20171013084702_GAO-ET-AL-2002","unstructured":"Gao Z , Matsuo H, Nakago S, Kurachi O and Maruo T (2002) p53 Tumor suppressor protein content in human uterine leiomyomas and its down-regulation by 17 beta-estradiol. J Clin Endocrinol Metab87,3915\u20133920."},{"key":"key\n\t\t\t\t20171013084702_HOUSTON-ET-AL-2003","unstructured":"Houston KD , Copland JA, Broaddus RR, Gottardis MM, Fischer SM and Walker CL (2003) Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma. Cancer Res63,1221\u20131227."},{"key":"key\n\t\t\t\t20171013084702_HUANG-ET-AL-2002","doi-asserted-by":"crossref","unstructured":"Huang SC , Tang MJ, Hsu KF, Cheng YM and Chou CY (2002) Fas and its ligand, caspases, and BCL-2 expression in gonadotropin-releasing hormone agonist-treated uterine leiomyoma. J Clin Endocrinol Metab87,4580\u20134586.","DOI":"10.1210\/jc.2001-011968"},{"key":"key\n\t\t\t\t20171013084702_HUPFELD-WEISS-2001","doi-asserted-by":"crossref","unstructured":"Hupfeld CJ and Weiss RH (2001) TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27. Am J Physiol Endocrinol Metab281, E207\u2013E216.","DOI":"10.1152\/ajpendo.2001.281.2.E207"},{"key":"key\n\t\t\t\t20171013084702_KURACHI-ET-AL-2001","unstructured":"Kurachi O , Matsuo H, Samoto T and Maruo T (2001) Tumor necrosis factor-alpha expression in human uterine leiomyoma and its down-regulation by progesterone. J Clin Endocrinol Metab86,2275\u20132280."},{"key":"key\n\t\t\t\t20171013084702_LEE-NOWAK-2001","unstructured":"Lee BS and Nowak RA (2001) Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab86,913\u2013920."},{"key":"key\n\t\t\t\t20171013084702_LOY-ET-AL-2003","doi-asserted-by":"crossref","unstructured":"Loy CJ , Sim KS and Yong EL (2003) Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci USA100,4562\u20134567.","DOI":"10.1073\/pnas.0736237100"},{"key":"key\n\t\t\t\t20171013084702_MARRET-ET-AL-2005","doi-asserted-by":"crossref","unstructured":"Marret H , Cottier JP, Alonso AM, Giraudeau B, Body G and Herbreteau D (2005) Predictive factors for fibroids recurrence after uterine artery embolisation. BJOG112,461\u2013465.","DOI":"10.1111\/j.1471-0528.2004.00487.x"},{"key":"key\n\t\t\t\t20171013084702_MASON-ET-AL-2003","doi-asserted-by":"crossref","unstructured":"Mason HR , Nowak RA, Morton CC and Castellot JJ Jr (2003) Heparin inhibits the motility and proliferation of human myometrial and leiomyoma smooth muscle cells. Am J Pathol162,1895\u20131904.","DOI":"10.1016\/S0002-9440(10)64323-4"},{"key":"key\n\t\t\t\t20171013084702_MCKENNA-OMALLEY-2002","doi-asserted-by":"crossref","unstructured":"McKenna NJ and O\u2019Malley BW (2002) Combinatorial control of gene expression by nuclear receptors and coregulators. Cell108,465\u2013474.","DOI":"10.1016\/S0092-8674(02)00641-4"},{"key":"key\n\t\t\t\t20171013084702_MICHALIK-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Michalik L , Desvergne B and Wahli W (2004) Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer4,61\u201370.","DOI":"10.1038\/nrc1254"},{"key":"key\n\t\t\t\t20171013084702_MOTOMURA-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Motomura W , Takahashi N, Nagamine M, Sawamukai M, Tanno S, Kohgo Y and Okumura T (2004) Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer108,41\u201346.","DOI":"10.1002\/ijc.11561"},{"key":"key\n\t\t\t\t20171013084702_NOWAK-2001","doi-asserted-by":"crossref","unstructured":"Nowak RA (2001) Identification of new therapies for leiomyomas: what in vitro studies can tell us. Clin Obstet Gynecol44,327\u2013334.","DOI":"10.1097\/00003081-200106000-00019"},{"key":"key\n\t\t\t\t20171013084702_QIN-ET-AL-2003","unstructured":"Qin C , Burghardt R, Smith R, Wormke M, Stewart J and Safe S (2003) Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res63,958\u2013964."},{"key":"key\n\t\t\t\t20171013084702_SATO-ET-AL-1998","doi-asserted-by":"crossref","unstructured":"Sato F , Nishi M, Kudo R and Miyake H (1998) Body fat distribution and uterine leiomyomas. J Epidemiol8,176\u2013180.","DOI":"10.2188\/jea.8.176"},{"key":"key\n\t\t\t\t20171013084702_SCHMIDT-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Schmidt S , Moric E, Schmidt M, Sastre M, Feinstein DL and Heneka MT (2004) Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol75,478\u2013485.","DOI":"10.1189\/jlb.0803402"},{"key":"key\n\t\t\t\t20171013084702_SHIKORA-ET-AL-1991","unstructured":"Shikora SA , Niloff JM, Bistrian BR, Forse RA and Blackburn GL (1991) Relationship between obesity and uterine leiomyomata. Nutrition7,251\u2013255."},{"key":"key\n\t\t\t\t20171013084702_SHIME-ET-AL-2002","doi-asserted-by":"crossref","unstructured":"Shime H , Kariya M, Orii A, Momma C, Kanamori T, Fukuhara K, Kusakari T, Tsuruta Y, Takakura K, Nikaido T et al. (2002) Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21 (waf1) and p53. J Clin Endocrinol Metab87,5610\u20135617.","DOI":"10.1210\/jc.2002-020444"},{"key":"key\n\t\t\t\t20171013084702_STEWART-2001","doi-asserted-by":"crossref","unstructured":"Stewart EA (2001) Uterine fibroids. Lancet357,293\u2013298.","DOI":"10.1016\/S0140-6736(00)03622-9"},{"key":"key\n\t\t\t\t20171013084702_TAKAGI-ET-AL-2003","doi-asserted-by":"crossref","unstructured":"Takagi T , Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K et al. (2003) Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J146, E5.","DOI":"10.1016\/S0002-8703(03)00146-7"},{"key":"key\n\t\t\t\t20171013084702_TSIBRIS-ET-AL-1999","unstructured":"Tsibris JC , Porter KB, Jazayeri A, Tzimas G, Nau H, Huang H, Kuparadze K, Porter GW, O\u2019Brien WF and Spellacy WN (1999) Human uterine leiomyomata express higher levels of peroxisome proliferator-activated receptor gamma, retinoid X receptor alpha, and all-trans retinoic acid than myometrium. Cancer Res59,5737\u20135744."},{"key":"key\n\t\t\t\t20171013084702_WANG-KILGORE-2002","doi-asserted-by":"crossref","unstructured":"Wang X and Kilgore MW (2002) Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells. Mol Cell Endocrinol194,123\u2013133.","DOI":"10.1016\/S0303-7207(02)00154-5"},{"key":"key\n\t\t\t\t20171013084702_WANG-ET-AL-2001","doi-asserted-by":"crossref","unstructured":"Wang Q , Lu J and Yong EL (2001) Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J Biol Chem276,7493\u20137499.","DOI":"10.1074\/jbc.M009916200"},{"key":"key\n\t\t\t\t20171013084702_XU-ET-AL-2003","doi-asserted-by":"crossref","unstructured":"Xu J , Luo X and Chegini N (2003) Differential expression, regulation, and induction of Smads, transforming growth factor-beta signal transduction pathway in leiomyoma, and myometrial smooth muscle cells and alteration by gonadotropin-releasing hormone analog. J Clin Endocrinol Metab88,1350\u20131361.","DOI":"10.1210\/jc.2002-021325"},{"key":"key\n\t\t\t\t20171013084702_YIN-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Yin F , Bruemmer D, Blaschke F, Hsueh WA, Law RE and Herle AJ (2004) Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene23,4614\u20134623.","DOI":"10.1038\/sj.onc.1207598"},{"key":"key\n\t\t\t\t20171013084702_YOUNG-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Young SL , Al-Hendy A and Copland JA (2004) Potential nonhormonal therapeutics for medical treatment of leiomyomas. Semin Reprod Med22,121\u2013130.","DOI":"10.1055\/s-2004-828618"},{"key":"key\n\t\t\t\t20171013084702_ZANCHI-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Zanchi A , Chiolero A, Maillard M, Nussberger J, Brunner HR and Burnier M (2004) Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab89,1140\u20131145.","DOI":"10.1210\/jc.2003-031526"},{"key":"key\n\t\t\t\t20171013084702_ZANG-ET-AL-2004","doi-asserted-by":"crossref","unstructured":"Zang C , Liu H, Posch MG, Waechter M, Facklam M, Fenner MH, Ruthardt M, Possinger K, Phillip Koeffler H and Elstner E (2004) Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Leuk Res28,387\u2013397.","DOI":"10.1016\/j.leukres.2003.07.005"}],"container-title":["MHR: Basic science of reproductive medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/molehr\/article-pdf\/11\/8\/561\/3704938\/gah199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T06:38:39Z","timestamp":1552113519000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/molehr\/article\/11\/8\/561\/1071267\/Growth-dynamics-of-human-leiomyoma-cells-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,28]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2005,6,28]]},"published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/molehr\/gah199","relation":{},"ISSN":["1460-2407","1360-9947"],"issn-type":[{"value":"1460-2407","type":"electronic"},{"value":"1360-9947","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,8]]},"published":{"date-parts":[[2005,6,28]]}}}